MedTrace Logo

Early Levothyroxine Post Radioactive Iodine

NCT01950260 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2019-10-29

Study results available
· View outcomes & findings →

Summary

The study will try to answer the question of whether early treatment with levothyroxine at 4 weeks after radioactive iodine for Graves'disease will prevent overt hypothyroidism (low thyroid hormone levels).

Conditions

  • Graves' Disease

Interventions

DRUG

Levothyroxine

Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).

OTHER

Placebo

Placebo to start at 4 weeks after RAI

Sponsors & Collaborators

Principal Investigators

  • Marius Stan, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2017-04-30
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01950260 on ClinicalTrials.gov